生物化药物。 2022年8月; 152：113204。 EPUB 2022 5月30日。PMID： 35653891“> 35653891” Wang，Ruizhu Jiang，Tiejian Zhao
文章隶属关系：Yang Zheng
摘要：
客观： 肝纤维化是可逆的病理学过程，是一种可逆性的病理学和治疗，其预防性和治疗对患者的病例具有很高的意义。这项研究结合了肠道菌群和血清代谢组学的16S rRNA分析，以探索姜黄素对小鼠肝纤维化的影响。结果s clarified the relationship between the gut microbiota and metabolites in the process of liver fibrosis.
MATERIALS AND METHODS: In this study, we randomly divided mice into a control group, a model group, and a curcumol treatment group to analyze the pathological changes in the liver tissue as well as the activities of the Toll样受体4（TLR4）/核工厂Kappa B（NF-κB）信号通路和炎症因子，例如肿瘤坏死因子（TNF），白介素6（IL-6）和IL-8。 The gut microbiota were analyzed by 16 S rRNA sequencing, and serum metabolites were examined by liquid chromatography-mass spectrometry (LC-MS) metabolomic analysis.
RESULTS: Molecular biological testing found that curcumol could significantly improve the pathological changes of the liver tissue并抑制肝脏炎症的发生。肠菌群测试发现姜黄素可能会大大改变Veillonellaceae，Prerotella_oulorum和Alistipes_finegoldii的丰富性。代谢组学分析发现，姜黄素抗肝纤维化作用可能与其对花生四烯酸代谢的调节有关。 Correlation analysis suggested that curcumol regulated the abundances of Bacteroidota and Bacteroides and participated in the metabolism of Prostaglandin B2.
CONCLUSIONS: When liver fibrosis occurs, the intestinal flora and metabolic network are altered.姜黄素对肝纤维化的影响可能与其对肠菌群的调节有关，并导致对代谢途径的干扰，从而减少肝脏炎症。
>